Long-term survival among Hodgkin lymphoma (HL) patients with gastrointestinal (GI) cancers: A population-based study.

Authors

null

P. Youn

Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY

P. Youn , H. Li , M. T. Milano , M. Stovall , L. S. Constine , L. B. Travis

Organizations

Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, New York University, New York, NY, University of Texas M. D. Anderson Cancer Center, Houston, TX, University of Rochester, Rochester, NY, University of Rochester School of Medicine and Dentistry, Rochester, NY

Research Funding

No funding sources reported

Background: The markedly increased risk of GI cancers after HL is well-established, with GI tumors accounting for the 3rd largest absolute risk of second cancers. However, no large, population-based studies have described overall survival (OS) and cause-specific survival (CSS) of HL survivors who developed GI cancers (HL-GI). Methods: For 209 HL-GI patients (105 colon, 35 stomach, 30 pancreas, 21 rectum, 18 esophagus) and 484,165 patients with first primary GI cancers (GI-1), actuarial OS and CSS were compared, accounting for age, gender, race, SES, GI cancer stage, radiation (RT) for HL, and other variables. Radiation doses to ascending, transverse, and descending colon with standard para-aortic and inverted-Y RT fields were estimated using water and anthropomorphic phantoms. Results: Survival of HL-GI group was inferior compared to GI-1 for most sites (Table). For localized stomach cancer, OS was more than three times worse among HL survivors. Whereas survival of HL patients who developed localized colon cancer (CC) was similar to that of GI-1 group, OS of HL patients with regional or distant CC was reduced 50%. HL survivors with regional or distant CC (transverse segment) had especially high risks of mortality (hazard ratios: 2.7 and 2.6; P=0.001 and 0.002 for OS and CSS respectively). Despite similarities in GI cancer stage between most HL-GI and GI-1 sites, transverse colon cancer was diagnosed at significantly more advanced stages in HL-GI vs. GI-1 (P=0.024). Dosimetry modeling of abdominal RT showed that transverse colon received 81% of total dose (vs. 4-43% to other segments). Conclusions: HL patients who develop GI cancer have significantly reduced survival compared to patients with a first primary cancer in GI sites. Further research is needed to explain the inferior survival of HL patients and to define selection criteria for screening colonoscopies in HL survivors.


OS hazard ratios (HR) from Cox model.
Localized Regional/distant
GI cancer site HR (P value) HR (P value)

Colon 1.3 (0.40) 1.5 (0.01)
Stomach 3.5 (0.006) 1.0 (0.8)
Pancreas Sample size too small for analysis 1.1 (0.6)
Rectum 1.7 (0.19) 2.1 (0.06)
Esophagus 4.3 (0.012) 0.8 (0.46)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Citation

J Clin Oncol 29: 2011 (suppl; abstr 8037)

Abstract #

8037

Poster Bd #

44A

Abstract Disclosures

Similar Abstracts

First Author: Mark Bilinyi Ulanja

Abstract

2017 Gastrointestinal Cancers Symposium

Long-term survival of gastrointestinal cancer diagnosed in Hodgkin lymphoma survivors.

First Author: Lisanne Sara Rigter

First Author: Antoine Adenis

First Author: Jamie Michelle Shoag